FDA grants orphan drug status to NovelMed’s PNH treatment

16 Apr 2024
www.pharmaceutical-technology.com
Phase 1Orphan Drug
Breakdown of PNH RBCs within and outside the blood vessels. Credit: Phonlamai Photo / Shutterstock.com.
NovelMed has announced the receipt of orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its investigational drug, NM5072, for treating paroxysmal nocturnal hemoglobinuria (PNH).
NovelMednative pathway blocker anti-properdin antibody, NM5072 selectively hiUS Food and Drug Administration (FDA)sponsible for the disease, inhiNM5072 alternative paparoxysmal nocturnal hemoglobinuria (PNH)f PNH red blood cells (RBCs).
By blocking the function of properdin, NM5072 prevents tNM5072akdown of PNH RBCs, which is central to the anaemia associated with PNH.
The drug has concluded a Phase I clinicNM5072al in 48 healthy volunteers with a good safety profile.anaemiaPNH
It is currently being reviewed for multiple indications by regulators in the US and internationally.
See Also:
Qureight secures Series A funding to accelerate drug development
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
PNH is a rare disease characterised by chronic inflammation and haemolysis, in which PNH RBCs break down within and outside blood vessels, leading to anaemia and severe health implications.
FDA072, wiNeumoralonschizophrenia, represents a siconvulsionsdvancement in the biologic treatment of PNH to improve patient outcomes.
NovelMed CEO Dr Rekha Bansal stated: “PNH is a rare disease that involves a range of blood cells that contribute to debilitating symptoms for patients, including anaemia, fatigue and severe pain with a shorter life span if it remains untreated.
PNH are hopeful that NM5072, with its uchronic inflammationction that targets the top of the complement cascade, could become a promising treatment toanaemiae outcomes in these patients.”
NM5072A’s ODD provides benefits including seven years of market exclusivity upon the receipt of approPNH, tax credits for clinical trial costs, fee waivers, reduced annual product fees, assistance for clinical protocol development and the possibility of expedited development programmes.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.